Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
- Conditions
- Interventions
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT00385827
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 275
- Registration Number
- NCT00381680
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸Childrens Memorial Hospital, Chicago, Illinois, United States
Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2024-02-22
- Target Recruit Count
- 1158
- Registration Number
- NCT00379041
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-09-15
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 68
- Registration Number
- NCT00376961
- Locations
- 🇺🇸
Tammy Walker Cancer Center at Salina Regional Health Center, Salina, Kansas, United States
🇺🇸Alaska Regional Hospital Cancer Center, Anchorage, Alaska, United States
🇺🇸Providence Cancer Center, Anchorage, Alaska, United States
Single Center Pilot Study of Corticosteroid Discontinuation in Liver Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2006-09-11
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 40
- Registration Number
- NCT00374231
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
Prednisone for Decompensated Congestive Heart Failure
- Conditions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2009-04-08
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 60
- Registration Number
- NCT00369044
- Locations
- 🇨🇳
The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Cortisone or Drug Eluting Stents (DES) as Compared to Bare Metal Stents (BMS) to EliminAte Restenosis
- Conditions
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- Universita di Verona
- Target Recruit Count
- 375
- Registration Number
- NCT00369356
- Locations
- 🇮🇹
Ospedale San Giovanni Bosco, Torino, Italy
🇮🇹European Hospital, Rome, Italy
🇮🇹Istituto Clinico Humanitas, Milano, Italy
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-08-17
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6
- Registration Number
- NCT00365274
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Toronto Sunnybrook Regional Cancer Centre
- Target Recruit Count
- 84
- Registration Number
- NCT00363090
- Locations
- 🇨🇦
St. Paul's Hospital at Providence Health Care - Vancouver, Vancouver, British Columbia, Canada
🇨🇦Odette Cancer Centre at Sunnybrook, Toronto, Ontario, Canada
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
Cell Biology of Steroid Resistant Asthma
- Conditions
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- National Jewish Health
- Target Recruit Count
- 40
- Registration Number
- NCT00361920
- Locations
- 🇺🇸
National Jewish Medical and Research Center, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.